The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Gene Dosage of the Amyloid β Precursor Protein in Alzheimer's Disease
Abstract
The progressive deposition in the human brain of amyloid filaments composed of the amyloid β protein is a principal feature of Alzheimer's disease (AD). Densitometric analysis of Southern blots probed with a complementary DNA for the amyloid protein has been carried out to determine the relative dosage of this gene in genomic DNA of 14 patients with AD, 12 aged normal subjects, and 10 patients with trisomy 21 (Down syndrome). Whereas patients in the last group showed the expected 1.5-fold increase in dosage of this gene, none of the patients with AD had a gene dosage higher than that of the normal controls. These results do not support the hypothesis that the genetic defect in AD involves duplication of a segment of chromosome 21 containing the amyloid gene. Alternative mechanisms for the brain-specific increase in amyloid protein deposition in AD should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
Cited by
Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity
Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S., & Ito, H. (1988) · Nature · doi:10.1038/331530a0 · Cited by 1,086
A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors
Ponte, P., DeWhitt, P. G., Schilling, J., Miller, J., Hsu, D., Greenberg, B., Davis, K., Wallace, W., Lieberburg, I., Fuller, F., et al. (1988) · Nature · doi:10.1038/331525a0 · Cited by 1,052
Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease
Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., Hockey, A., Montgomery, P., Beyreuther, K., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 653
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Selkoe, D. J., Podlisny, M. B., Joachim, C. L., Vickers, E. A., Lee, G., Fritz, L. C., & Oltersdorf, T. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7341 · Cited by 583
Self-citationThe Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Evidence for a membrane defect in Alzheimer disease brain.
Nitsch, R. M., Blusztajn, J. K., Pittas, A. G., Slack, B. E., Growdon, J. H., & Wurtman, R. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1671 · Cited by 536
Amyloid β Protein Enhances the Survival of Hippocampal Neurons in Vitro
Whitson, J. S., Selkoe, D. J., & Cotman, C. W. (1989) · Science · doi:10.1126/science.2928783 · Cited by 470
Self-citationAlterations of the microRNA network cause neurodegenerative disease
Hébert, S. S., & De Strooper, B. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.003 · Cited by 452
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442
MicroRNA regulation of Alzheimer's Amyloid precursor protein expression
Hébert, S. S., Horré, K., Nicolaï, L., Bergmans, B., Papadopoulou, A. S., Delacourte, A., & De Strooper, B. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.009 · Cited by 436
Golde, T. E., Estus, S., Usiak, M., Younkin, L. H., & Younkin, S. G. (1990) · Neuron · doi:10.1016/0896-6273(90)90100-t · Cited by 432
Expression of the Alzheimer amyloid precursor gene transcripts in the human brain
NEVE, R. (1988) · Neuron · doi:10.1016/0896-6273(88)90166-3 · Cited by 388
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
Constitutional Aneuploidy in the Normal Human Brain
Rehen, S. K., Yung, Y. C., McCreight, M. P., Kaushal, D., Yang, A. H., Almeida, B. S. V., Kingsbury, M. A., Cabral, K. M. S., McConnell, M. J., Anliker, B., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4560-04.2005 · Cited by 319
MicroRNAs in Alzheimer’s Disease
Wang, M., Qin, L., & Tang, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00153 · Cited by 307
Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome.
Rahmani, Z., Blouin, J. L., Creau-Goldberg, N., Watkins, P. C., Mattei, J. F., Poissonnier, M., Prieur, M., Chettouh, Z., Nicole, A., & Aurias, A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5958 · Cited by 258
Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid-β
Schonrock, N., Ke, Y. D., Humphreys, D., Staufenbiel, M., Ittner, L. M., Preiss, T., & Götz, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011070 · Cited by 211
Circulating miRNAs as Biomarkers for Neurodegenerative Disorders
Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. (2014) · Molecules · doi:10.3390/molecules19056891 · Cited by 208
“let-7 family, miR-17-5p, miR-20a miR-106b APP Oncogene, over-expressed in oral cavity, esophageal, pancreatic, neuroendocrine, thyroid, and colorectal cancer Concentrated at neuronal synapses and in AD-associated amyloid plaques [69–76]”
BackgroundMicroRNAs in neurodegenerative diseases and their therapeutic potential
Junn, E., & Mouradian, M. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.10.002 · Cited by 186
MicroRNAs in Alzheimer's disease
Delay, C., Mandemakers, W., & Hébert, S. S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.003 · Cited by 185
Joachim, C. L., Duffy, L. K., Morris, J. H., & Selkoe, D. J. (1988) · Brain Research · doi:10.1016/0006-8993(88)90673-7 · Cited by 180
Self-citationBushman, D. M., Kaeser, G. E., Siddoway, B., Westra, J. W., Rivera, R. R., Rehen, S. K., Yung, Y. C., & Chun, J. (2015) · eLife · doi:10.7554/elife.05116 · Cited by 136
“…in sporadic AD are consistent with prior studies in both peripheral non-brain and intact brain tissues, which reported APP levels approximating 2N (Podlisny et al., 1987; St George-Hyslop et al., 1987; Tanzi et al., 1987; Bertram et al., 2010), and is further consistent with mosaic CNVs observed…”
BackgroundResultInfluentialThe Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Vassar, R., & Cole, S. (2007) · Current Genomics · doi:10.2174/138920207783769512 · Cited by 84
Li, S., Yan, Y., Jiao, Y., Gao, Z., Xia, Y., Kong, L., Yao, Y., Tao, Z., Song, J., Yan, Y., et al. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0793-9 · Cited by 55
Metadata
- Authors
- Podlisny, M. B., Lee, G., & Selkoe, D. J.
- Venue
- Science
- Published
- 1987-10-30
- Volume
- 238
- Issue
- 4827
- Pages
- 669-671
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1996132904
- Cited by
- 175
- References
- 3
- FWCI
- 25.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.